SYBX - Synlogic to Participate in Chardan's Genetic Medicines Conference | Benzinga
CAMBRIDGE, Mass., Sept. 21, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (NASDAQ:SYBX), a clinical-stage biotechnology company advancing novel, oral, non-systemically absorbed biotherapeutics to transform the care of serious diseases, today announced its management team will participate in Chardan's 7th Annual Genetic Medicines Conference, being held in New York, October 2-3, 2023. In addition to one-on-one meetings with investors, Synlogic CEO Dr. Aoife Brennan will participate in a Fireside Chat on Monday, October 2 at 4:30 p.m. Eastern Time.
A live webcast of the fireside chat will be available in the investor section of the company's website at www.synlogictx.com, and will be available for replay after the conference.
To register for the conference or request one-on-one meetings, please contact your Chardan representative.
About Synlogic
Synlogic is a clinical-stage biotechnology company advancing novel, oral, non-systemically absorbed biotherapeutics to transform the care of serious diseases in need of new treatment options. The Company's late-stage pipeline is focused on rare metabolic diseases, led by labafenogene marselecobac (SYNB1934), currently being studied as a potential treatment for phenylketonuria (PKU) in Synpheny-3, a global, pivotal Phase 3 study. Additional product candidates address diseases including homocystinuria (HCU), enteric hyperoxaluria, gout, and cystinuria. ...